X-Chem, a global leader in innovative drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership dedicated to accelerating drug discovery through open science, announced that they have entered a collaboration aimed at creating new chemical tools to study human proteins. The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome — ultimately allowing drug discovery and machine learning (ML) experts from around the world to use the data to unlock disease targets of the future.
Under the agreement, X-Chem will deploy its proprietary DEL platform to create datasets for proteins chosen and supplied by the SGC. These datasets, curated in an ML-ready format, will be posted to a public portal to be used for model building. These models will enable the development of tool compounds that will unlock future disease targets, a key goal of the SGC’s Target 2035 initiative. The early stages of the collaboration will be focused on screening and data generation, but X-Chem and the SGC expect the DEL-ML data portal will be ready for public access starting in early 2024.
“X-Chem was the first to show that high-quality DEL datasets can support model building, and our successful collaboration with X-Chem on multiple unprecedented targets supports the scaling of their innovative approach,” said Aled Edwards, S.G., Ph.D., founder and CEO of the SGC. “We look forward to making our screening data publicly available so as to enable biological and computational researchers worldwide to collaborate openly with us to identify the disease targets of the future.”
Matt Clark, Ph.D., CEO of X-Chem, said, “The SGC is dedicated to unlocking the human proteome through innovative science and open collaboration. We are thrilled that X-Chem will be a partner in their mission to understand all proteins in the human genome. Our DEL platform is the perfect technology for such high-throughput, high-quality data generation.”
About X-Chem
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI.
About the Structural Genomics Consortium
The Structural Genomics Consortium is a global public-private partnership that seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and making all research outputs openly available to the scientific community. The current SGC research sites are located at Goethe University in Frankfurt, Karolinska Institute, McGill University, University College, London, the University of North Carolina, Chapel Hill, and the University of Toronto.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230928544818/en/
In a new collaboration between @XchemInc and @thesgconline, DNA-encoded library (DEL) screening data will be generated for large numbers of under-addressed proteins in the human proteome, which will ultimately be available for public access.
Contacts
Lindsey Langemeier
SCORR Marketing
402-405-4269
lindsey@scorrmarketing.com
